Grand Rapids, MI – March 3, 2025 — NxGen MDx, a leader in innovative laboratory testing, proudly announces the launch of the Total Insight Pregnancy Panel™, a groundbreaking solution that integrates three essential testing tools: Carrier Screening, Non-Invasive Prenatal Testing (NIPT), and an Advanced UTI Panel. This comprehensive panel is designed to provide unparalleled insights into maternal and fetal health, enabling healthcare providers to address genetic, microbiological, and infectious risks that could impact pregnancy outcomes. 

The Total Insight Pregnancy Panel™ combines advanced testing technologies to ensure the best possible care for expectant mothers and their babies. The Super Panel screens for over 145 genetic conditions, providing results in approximately two weeks through a simple blood draw. It offers industry-leading At-Risk Couple detection, enabling healthcare  providers to identify genetic risks early. The Non-Invasive Prenatal Testing (NIPT) delivers results in about one week with an exceptionally low No-Call Rate. It also includes options for detecting microdeletions, expanded aneuploidies, and Fetal RhD status, offering a more informed approach to prenatal care. The Advanced UTI Panel provides results within 24 hours and incorporates PCR-based detection of 27 pathogens, covering 99% of  community-acquired infections. This panel also includes simultaneous Antibiotic Resistance (ABR) testing, ensuring targeted and effective treatment plans. 

Comprehensive testing is a critical component of maternal and fetal health. The inclusion of a UTI panel is critical, as up to 8% of all pregnancies are affected, and early action may be necessary (ACOG 2023). Traditional methods often fail to identify key infections and genetic conditions, increasing the risk of preterm labor, low birth weight, and neonatal infections. The NxGen Total Insight Pregnancy Panel™ addresses these gaps by integrating genetic screening and infection testing into a single, streamlined solution. This approach empowers healthcare providers with a holistic  understanding of potential risks, enabling timely and informed interventions. This tool is curated based on the latest scientific research and societal guidelines, including  those from the Centers for Disease Control and Prevention (CDC) and the American College  of Obstetricians and Gynecologists (ACOG). 

“The Total Insight Pregnancy Panel™ reflects NxGen MDx’s commitment to delivering cutting-edge laboratory solutions that address the most pressing challenges in maternal and fetal healthcare,” said Alan Mack, Founder and CEO of NxGen MDx. “By combining genetic screening and infectious disease diagnostics, we’re setting a new standard for comprehensive pregnancy care.”